Clinical Pharmacodynamics, Pharmacokinetics, and Drug Interaction Profile of Doravirine

Clinical Pharmacokinetics
Alison BoyleSaye Khoo

Abstract

Doravirine is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) that has demonstrated good efficacy, tolerability, and safety for the treatment of patients with human immunodeficiency virus (HIV)-1 infection in phase III clinical trials. Doravirine achieved non-inferiority when compared with efavirenz- and darunavir/ritonavir-based regimens. Fewer adverse effects, including neuropsychiatric effects were observed with doravirine compared with efavirenz. Key pharmacodynamic and pharmacokinetic characteristics as well as drug-drug interactions and the resistance profile were assessed in this clinical review. Doravirine is a pyridinone NNRTI with potent antiviral activity against wild-type HIV-1 virus and common NNRTI variants. Studies in healthy volunteers and HIV-infected individuals have shown that doravirine has a favorable pharmacokinetic profile for once-daily dosing, with an elimination half-life of around 15 h, median time to maximum plasma concentrations of 1-4 h, and time to steady-state concentration of 7 days. The pharmacokinetics of doravirine are not greatly influenced by sex, age, race, or hepatic impairment. Although no dose adjustment is required for doravirine in renal impairment when given as a singl...Continue Reading

References

Nov 16, 2001·Revista Panamericana De Salud Pública = Pan American Journal of Public Health·UNKNOWN Panel on Clinical Practices for Treatment of HIV infection
Mar 21, 2007·Applied Microbiology and Biotechnology·Yazan El SafadiRoland Marquet
Jan 1, 2014·Antimicrobial Agents and Chemotherapy·Ming-Tain LaiMichael D Miller
Oct 5, 2016·Clinical Pharmacokinetics·Matt S AndersonJoan R Butterton
Nov 23, 2016·Antimicrobial Agents and Chemotherapy·Ka Lai YeeSauzanne G Khalilieh
Nov 23, 2016·Antimicrobial Agents and Chemotherapy·Sauzanne KhaliliehMarian Iwamoto
Dec 28, 2016·Journal of Clinical Pharmacology·Sauzanne KhaliliehMarian Iwamoto
Mar 21, 2018·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Rosa I SanchezSauzanne G Khalilieh
May 4, 2018·Journal of Clinical Pharmacology·Sauzanne G KhaliliehMarian Iwamoto
Jun 13, 2018·Antimicrobial Agents and Chemotherapy·Wendy AnkromSauzanne G Khalilieh
Nov 27, 2018·The Journal of Antimicrobial Chemotherapy·Cathia SoulieAnne-Geneviève Marcelin
Feb 13, 2019·Antimicrobial Agents and Chemotherapy·Ka Lai YeeLarissa Wenning
Feb 13, 2019·Antimicrobial Agents and Chemotherapy·Kelly BleasbyRosa I Sanchez
Feb 16, 2019·International Journal of Antimicrobial Agents·Gaetana SterrantinoUNKNOWN ARCA Study Group
Feb 21, 2019·Antimicrobial Agents and Chemotherapy·Wendy AnkromSauzanne Khalilieh
Feb 21, 2019·Antimicrobial Agents and Chemotherapy·Sauzanne G KhaliliehMarian Iwamoto
Mar 1, 2019·Journal of Clinical Pharmacology·Sauzanne G KhaliliehMarian Iwamoto
May 24, 2019·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Chloe OrkinCarey Hwang

❮ Previous
Next ❯

Citations

Apr 10, 2020·Expert Opinion on Drug Metabolism & Toxicology·Megan NearyAdeniyi Olagunju
Jul 2, 2020·HIV/AIDS : Research and Palliative Care·Alexander E RockMelissa E Badowski
Nov 18, 2020·Current Opinion in Pharmacology·Murugesan VanangamudiVigneshwaran Namasivayam
Apr 15, 2021·The Pharmacogenomics Journal·Stefania CheliCristina Montrasio
Dec 2, 2021·AIDS·Phumla Z SinxadiMarta Boffito
Nov 6, 2021·Current Opinion in HIV and AIDS·Alexander J Stockdale, Saye Khoo

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.